Author: Galimedix Therapeutics, Inc.

Posted Date:

March 20, 2026

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Galimedix Therapeutics, Inc.

March 20, 2026
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation

Galimedix Therapeutics, Inc.

March 12, 2026
Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference

Galimedix Therapeutics, Inc.

March 5, 2026